After the publication of the 10-year survival data from Milan on the adjuvant use of the block sequential regimen consisting of four cycles of adriamycin followed by eight cycles of intravenous CMF, ...

New research shows that a combination of doxil, carboplatin and bevacizumab is a well-tolerated treatment regimen in patients with metastatic triple-negative breast cancer who received no prior ...

BRIDGEWATER, N.J., September 08, 2008 /PRNewswire/ -- Ortho Biotech Products, L.P. today announced that the Company has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug ...

Epithelial ovarian cancer (EOC) is the fifth commonest cancer in women and despite the use of platinum-based chemotherapy, the prognosis for women with advanced disease remains poor with a 5-year ...

Get local context for national news. Subscribe to Daily Digger, the Vermont newsletter 28,000 people rely on. Delivered to your inbox every Mon – Sat. Commentaries are opinion pieces contributed by ...

Findings from a randomized phase 3 study showed that adding neoadjuvant Tecentriq to a chemotherapy regimen of Abraxane, Adriamycin and Cytoxan in patients with stage 2 or 3 triple-negative breast ...

It's just a minor reprieve, though. There's about enough of the short-supply drug for 1,000 patients, so it will go only to those already on a regimen; about 2,700 remain wait-listed. The Doxil ...

Treating women with early stage breast cancer with a combination of chemotherapy and the molecularly targeted drug Herceptin significantly increases survival in patients with a specific genetic ...